Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ceapro Inc V.CZO

Alternate Symbol(s):  CRPOF

Chemicals Specialty Chemicals
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

Recent & Breaking News (TSXV:CZO)

Ceapro Announces Results of 2023 Shareholders' Meeting

GlobeNewswire June 7, 2023

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

GlobeNewswire May 25, 2023

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

GlobeNewswire May 23, 2023

Ceapro's findings demonstrate oat derived beta glucan and avenanthramides promote wound healing and tissue regeneration

Shoran Devi May 3, 2023

Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration

GlobeNewswire May 3, 2023

Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations

GlobeNewswire April 27, 2023

Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights

GlobeNewswire April 12, 2023

Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference

GlobeNewswire March 23, 2023

Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society

GlobeNewswire March 8, 2023

Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company

GlobeNewswire February 21, 2023

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

Accesswire January 11, 2023

Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event

GlobeNewswire January 10, 2023

Ceapro Announces Grant of Stock Options

GlobeNewswire January 4, 2023

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets

GlobeNewswire December 22, 2022

Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights

GlobeNewswire November 9, 2022

Ceapro (TSXV:CZO) launches next scale up phase for nutraceutical & pharmaceutical product development

Jonathon Brown November 7, 2022

Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

GlobeNewswire November 7, 2022

Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

GlobeNewswire October 13, 2022

Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update

GlobeNewswire August 24, 2022

Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis

GlobeNewswire August 11, 2022